Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$141.75 USD

141.75
681,591

+2.42 (1.74%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks News

GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y

GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.

    Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT

    Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.

      LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View

      Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.

        Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View

        Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.

          Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss

          Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.

            Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter

            Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.

              CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

              CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.

                Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal

                Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).

                  Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4

                  Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny

                    Genomic Health (GHDX) Earnings Surpass Estimates in Q4

                    Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.

                      Becton, Dickinson Launches BD Resolve Early Access Program

                      Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.

                        Medtronic (MDT) Adds New Tools, Expands Coronary Suite

                        Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.

                          Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance

                          Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.

                            Omnicell Partners with DCH Health for Sterile Compounding

                            Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.

                              Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals

                              Varian Medical Systems, Inc. (VAR) recently announced that it has won a competitive bid in Shanghai.

                                STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?

                                On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).

                                  Mead Johnson-Reckitt Benckiser Mega Deal: A Strategic Fit?

                                  Pediatric nutrition manufacturer Mead Johnson Nutrition Company (MJN) recently announced an agreement to be acquired by British consumer-products maker, Reckitt Benckiser Group plc.

                                    Cerner (CERN) Q4 Earnings Meet, Revenues Miss Estimates

                                    Cerner Corp(CERN) reported adjusted fourth-quarter 2016 earnings of 57 cents per share, in line with the Zacks Consensus Estimate.

                                      NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017

                                      NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.

                                        Will Glaukos (GKOS) Continue to Surge Higher?

                                        As of late, it has definitely been a great time to be an investor in Glaukos Corp (GKOS).

                                          Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag

                                          On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).

                                            Zimmer Biomet (ZBH) Launches Subchondroplasty Procedure

                                            Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the musculoskeletal healthcare space, recently announced the global launch of its Subchondroplasty (SCP) Procedure.

                                              CVS Health (CVS) Beats on Q4 Earnings, Retains '17 View

                                              CVS Health Corporation (CVS) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $1.71, up 11.8% year over year.

                                                Quest Diagnostics Partners with Veracyte for Cancer Testing

                                                Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).

                                                  Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View

                                                  Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.